BEBIG Medical

Executive Summary

BEBIG Medical GmbH, headquartered in Berlin, Germany, is a established player in the radiation therapy market with over 30 years of experience. The company offers a comprehensive portfolio including linear accelerators, HDR brachytherapy systems, X-ray therapy devices, and intraoperative radiation therapy (IORT) solutions, distributing to more than 90 countries via a network of 90+ distributors. Despite its long history and global reach, BEBIG remains a private entity with limited public disclosure, making it difficult to assess recent financial performance or growth trajectory. The company's focus on niche radiotherapy segments like IORT and HDR brachytherapy positions it well in the growing precision oncology market, but competition from larger players such as Elekta and Varian poses challenges. BEBIG's ability to innovate and expand its distribution in emerging markets will be key to maintaining its market share. Overall, the company appears stable but lacks near-term visibility, warranting a moderate conviction score.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation HDR brachytherapy afterloader65% success
• Q4 2026FDA clearance for updated IORT system50% success
• TBDExpansion of distributor network in Asia-Pacific70% success